Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide

Annals of Hematology

Volumn 83, Issue 7, 2004, Pages 467-470

  Witzens, Mathias ^a   Moehler, Thomas ^a   Neben, Kai ^b   Fruehauf, Stefan ^a   Hartschuh, Wolfgang ^c   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Leukocytoclastic vasculitis; Multiple myeloma; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IDARUBICIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INFECTION; KIDNEY DISEASE; LEPROSY; LEUKOCYTOCLASTIC VASCULITIS; MALE; MONOTHERAPY; MOOD DISORDER; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PATIENT MONITORING; PRIORITY JOURNAL; SEDATION; SKIN BIOPSY; SKIN EXFOLIATION; SOMNOLENCE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; IDARUBICIN; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISOLONE; PREDNISONE; THALIDOMIDE; VASCULITIS, HYPERSENSITIVITY; VINCRISTINE;

EID: 3042734353     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0804-0     Document Type: Article

References (31)

1. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K (2001) T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98:934-939
2. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085
3. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494
4. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216
5. Durie BGM, Stepan DE (2001) Low dose thalidomide alone and in combination: long term follow-up. Blood 98:688a
6. Farace F, Orlanducci F, Dietrich P-Y, Gaudin C, Angevin E, Courtier M-H, Bayle C, Hercend T, Triebel F (1994) T cell repertoire in patients with B chronic lymphocytic leukemia. J Immunol 153:4281-4290
7. Haslett PA, Corral LG, Albert M, et al. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892
8. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y-T, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950
9. Janson CH, Grunewald J, Österborg A, DerSimonian H, Brenner MB, Mellstedt H, Wigzell H (1991) Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77:1776-1780
10. Kay N, Leong T, Kyle RA, Greipp P, Van Ness B, Bone N, Oken MM (1999) Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 33:127-133
11. Keifer JA, Guttridge DC, Ashburner BP, et al. (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387
12. Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC (1999) Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 26:2344-2347
13. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98:3846-3848
14. + T cells in patients with multiple myeloma and paraproteinemia. Blood 87:3297-3306
15. Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD, Goldschmidt H (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605-608
16. Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 7:2675-2681
17. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377-3382
18. Or R, Feferman R, Shoshan S (1998) Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 26:217-221
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427
20. Rajkumar SV, Gertz MA, Witzig TE (2000) Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343:972-973
21. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323
22. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, Pope B, Esdale W, Gibson J, Joshua DE (2000) T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 110:203-209
23. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305:1222-1232
24. Shannon E, Aseffa A, Pankey G, Sandoval F, Lutz B (2000) Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 46:175-179
25. Shannon EJ, Sandoval FG (2002) Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine-dependence on the primary stimulant. Int Immunopharmacol 2:1143-1153
26. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
27. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, Baxter AG, Fazekas de St Groth B, Basten A, Joshua DE (2001) Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 98:2817-2827
28. Wen T, Mellstedt H, Jondal M (1990) Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 171:659-666
29. Wen YJ, Barlogie B, Yi Q (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 97:1750-1755
30. + subsets. Br J Haematol 96:338-345
31. Zwingenberger K, Wnendt S (1995-1996) Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J Inflamm 46:177-211